Starting from the structure of BAs and considering the convergence of both receptors in regulating several aspects of metabolic disorders, many synthetic ligands endowed with dual or selective activity toward GPBAR1 and FXR have been designed and developed for the treatment of NASH (Tiwari and Maiti, 2009; Fiorucci, et al., 2020; Ratziu et al., 2022). This evidence concerns the gene NR1H4 and metabolic dysfunction-associated steatohepatitis.